Clinical Trials on Mild to Moderate Psoriasis in Sweden

Total 14 results

Kristian Reich, MD
LEO Pharma

Completed

Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP) (PSO-TOP)

Mild to Moderate Psoriasis

United Kingdom, Germany, France, Spain, Netherlands, Sweden, Italy, Denmark
Göteborg University
University of Boras

Recruiting

Talking Mats as Decision Aid for Older People Living With Mild to Moderate Dementia

Mild to Moderate Dementia

Sweden
AbbVie (prior sponsor, Abbott)

Completed

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (LOTOS)

Moderate to Severe Plaque Psoriasis

Germany
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Mundipharma Research GmbH & Co KG

Completed

Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

Moderate to Severe Idiopathic RLS With Daytime Symptoms

Spain, Sweden, Germany
PharmatrophiX Inc.
National Institute on Aging (NIA)

Completed

Study of LM11A-31-BHS in Mild-moderate AD Patients

Mild to Moderate Alzheimer's Disease

Spain, Germany, Austria, Czechia, Sweden
Parc Sanitari Pere Virgili
Consorci Sanitari Integral; Vall d'Hebron Institute of Research; Health and Ageing... and other collaborators

Recruiting

IMAGINE Study Protocol (IMAGINE)

Patients (>=60 Years Old) Suffering From Mild-moderate Stroke (Ischemic or Hemorrhagic, Stroke Severity Assessed by NIHSS <16 Points)

Spain, Sweden
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines. (ULTRA II)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Germany
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
Vastra Gotaland Region
Göteborg University

Terminated

Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease (PULMORA)

Rheumatoid Arthritis | ILD | Interstitial Lung Disease Due to Systemic Disease (Disorder) | RA

Sweden
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia

Clinical Trials on Mild to Moderate Psoriasis in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations